Loading
Sagimet Biosciences Inc. Stock: price and insider trades · United States
US·Mcap US$568.7M
No insider purchase over the last 90 days. The latest was filed 28 Mar 2024.
Sagimet Biosciences Inc.: what insiders have been doing
This page follows insider dealings at Sagimet Biosciences Inc. as filed with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 22 filings signed by 6 insiders.
No insider bought on the market over the period, while 5 insiders filed 10 sales totalling €4.3M. At €3.1M, the sale published on 17 August 2026 by Kemble George is the largest of the period (0.63% of market cap).
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 22 filings here. The full history, which starts in 2023, counts 3 purchases against 17 sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
50
Thresholds
n/a
Buy Volume
€66,172
3 ops. · all time
Sell Volume
€5M
17 ops. · all time
Who traded when
BuySaleGeorge Kemble4 sales
David Happel3 sales
Elizabeth Rozek3 sales
Eduardo Bruno Martins2 sales
Thierry Chauche1 sale
Analyst consensus: bullish or bearish?
Analysts rate Sagimet Biosciences Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$27.91.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.02
Analyst consensus
11 analystsStrong buy
US$7.00Target US$27.91(+248%)US$56.00
Income statement
RevenueUS$1.7M
EBITDA-US$56.9M-3304% margin
Net income-US$51M0.0% margin
Valuation
PER (forward)-6.2x
P/Book1.9x
Beta3.49
Balance sheet & cash
Market capUS$568.7M
Total debtUS$78k
Free Cash Flow-US$45.7M
Debt / Equity1%
Profitability & ownership
ROE-24.4%
ROA-16.4%
% insiders3.0%
% institutions77.1%
Last declaration on 17 August 2026
Declarations50 total
326,618 shares@ US$6.360.36% mcap30.9% of flowSeries A Common StockSEC:0001193125-26-354018:0
24,369 shares@ US$6.360.027% mcap2.3% of flowSeries A Common StockSEC:0001193125-26-354018:1
350,987 shares@ US$10.23280.63% mcap53.5% of flowSeries A Common StockSEC:0001193125-26-354018:2
350,987 shares@ US$9.280.50% mcap95.6% of flowCommonSEC144:0001950047-26-008152
9,751 shares@ US$6.360.011% mcap0.9% of flowSeries A Common StockSEC:0001193125-26-347407:0
10,455 shares@ US$6.360.012% mcap1.0% of flowSeries A Common StockSEC:0001193125-26-347407:1
20,206 shares@ US$9.95480.035% mcap3.0% of flowSeries A Common StockSEC:0001193125-26-347407:2
20,206 shares@ US$9.570.034% mcap100.0% of flowCommonSEC144:0001950047-26-007964
10,545 shares@ US$7.76030.014% mcap36.0% of flowSeries A Common StockSEC:0001193125-26-312394:0
64,051 shares@ US$7.76050.087% mcap40.7% of flowSeries A Common StockSEC:0001193125-26-312397:0
18,844 shares@ US$7.45750.025% mcap2.1% of flowSeries A Common StockSEC:0001193125-26-312386:0
18,844 shares@ US$7.820.023% mcap4.4% of flowCommonSEC144:0001950047-26-007226
44,000 shares0Series A Common StockSEC:0001104659-26-018194:0
128,000 shares0Series A Common StockSEC:0001104659-26-018193:0
44,000 shares0Series A Common StockSEC:0001104659-26-018191:0
44,000 shares0Series A Common StockSEC:0001104659-26-018196:0
12,101 shares@ US$5.36035.1% of flowSeries A Common StockSEC:0001104659-26-014283:0
3,640 shares@ US$5.360215.6% of flowSeries A Common StockSEC:0001104659-26-014272:0
2,622 shares@ US$5.36025.9% of flowSeries A Common StockSEC:0001104659-26-014266:0
1,312 shares@ US$5.3603100.0% of flowSeries A Common StockSEC:0001104659-26-014277:0
37,688 shares@ US$7.69424.3% of flowSeries A Common StockSEC:0001104659-25-115071:0
9,855 shares0Series A Common StockSEC:0001104659-25-107806:0
10,780 shares@ US$9.134642.4% of flowSeries A Common StockSEC:0001104659-25-070013:0
65,478 shares@ US$9.134647.9% of flowSeries A Common StockSEC:0001104659-25-070017:0
8,277 shares@ US$9.134661.7% of flowSeries A Common StockSEC:0001104659-25-070015:0
25 of 50 declarations
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc. is a biopharmaceutical company focused on developing innovative treatments for metabolic diseases. The company is listed on NASDAQ under the ticker symbol SAGE.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
